DRY EYE SYNDROME: PATHOPHYSIOLOGY, DIAGNOSIS AND PREVENTIVE STRATEGIES
Article Sidebar
Main Article Content
Abstract
Dry Eye Syndrome (DES), also known as keratoconjunctivitis sicca (KCS), is a multifactorial disorder of the tear film and ocular surface, characterized by tear film instability, hyperosmolarity, ocular discomfort, and visual disturbances. DES affects millions worldwide, significantly reducing quality of life and productivity. This review synthesizes current scientific understanding of DES pathophysiology, risk factors, diagnostic criteria, and evidence-based preventive strategies.
Downloads
Article Details
Section
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
How to Cite
References
1. Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, et al. TFOS DEWS II Definition and Classification Report. Ocul Surf. 2017;15(3):276–283.
2. Stapleton F, Alves M, Bunya VY, Jalbert I, Lekhanont K, Malet F, et al. TFOS DEWS II Epidemiology Report. Ocul Surf. 2017;15(3):334–365.
3. Baudouin C, Messmer EM, Aragona P, Geerling G, Akova YA, Benitez-Del-Castillo J, et al. Revisiting the vicious circle of dry eye disease. Br J Ophthalmol. 2016;100(3):300–306.
4. Lemp MA, Bron AJ, Baudouin C, Benítez Del Castillo JM, Geffen D, Tauber J, et al. Tear osmolarity in the diagnosis and management of dry eye disease. Am J Ophthalmol. 2011;151(5):792–798.
5. Nelson JD, Craig JP, Akpek EK, Azar DT, Belmonte C, Bron AJ, et al. TFOS DEWS II Introduction. Ocul Surf. 2017;15(3):269–275.
6. Nichols KK, Foulks GN, Bron AJ, Glasgow BJ, Dogru M, Tsubota K, et al. The International Workshop on Meibomian Gland Dysfunction: Executive Summary. Invest Ophthalmol Vis Sci. 2011;52(4):1922–1929.
7. Bron AJ, de Paiva CS, Chauhan SK, Bonini S, Gabison EE, Jain S, et al. TFOS DEWS II Pathophysiology Report. Ocul Surf. 2017;15(3):438–510.
8. Jones L, Downie LE, Korb D, Benitez-del-Castillo JM, Dana R, Deng SX, et al. TFOS DEWS II Management and Therapy Report. Ocul Surf. 2017;15(3):575–628.
9. Miljanović B, Trivedi KA, Dana MR, Gilbard JP, Buring JE, Schaumberg DA. Relation between dietary n-3 and n-6 fatty acids and clinically diagnosed dry eye syndrome. Am J Clin Nutr. 2005;82(4):887–893.
10. Schaumberg DA, Sullivan DA, Buring JE, Dana MR. Prevalence of dry eye syndrome among US women. Am J Ophthalmol. 2003;136(2):318–326.
11. Messmer EM. The pathophysiology, diagnosis, and treatment of dry eye disease. Dtsch Arztebl Int. 2015;112(5):71–82.
12. McMonnies CW. Inflammation and dry eye. Clin Exp Optom. 2017;100(5):500–511.